Ferozsons Laboratories Limited (PSX: FEROZ) reported a 23% year-on-year increase in its consolidated net profit for the first quarter ended September 30, 2026 (1QFY27), surging to Rs 395.77 million compared to Rs 321.95 million in 1QFY26. Basic and diluted earnings per share (EPS) rose by 24.4% to Rs 7.40 from Rs 5.95 in the corresponding period last year.
Top-line growth served as the primary catalyst, with net revenue swelling 19.1% to Rs 7.07 billion against Rs 5.94 billion recorded in 1QFY26. Despite a 15% rise in cost of sales to Rs 3.83 billion, gross profit jumped 24.3% to Rs 3.24 billion, expanding the gross profit margin to 45.85% from 43.94% in the previous year. Selling and distribution expenses rose 26.6% to Rs 2.12 billion, while administrative expenses grew 15.6% to Rs 332.65 million. Profit from operations expanded 16.3% to Rs 748.05 million despite a 49.6% drop in other income.
| Financial Metric (PKR) | 1QFY27 | 1QFY26 | Change (%) |
|---|---|---|---|
| Net Revenue | 7,074,484,011 | 5,939,278,627 | 19.1% |
| Gross Profit | 3,243,884,378 | 2,609,462,004 | 24.3% |
| Operating Profit | 748,049,187 | 643,198,025 | 16.3% |
| Net Profit | 395,769,317 | 321,949,511 | 22.9% |
| EPS (PKR) | 7.40 | 5.95 | 24.4% |
Read the full story on the original publisher’s website.
Open original article